This site is intended for healthcare professionals
News

Xpovio approved by TGA (Australia) to treat multiple myeloma.- Antengene Corporation.

Read time: 1 mins
Published:15th Mar 2022

Antengene Corporation, announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered Xpovio (selinexor) for two indications

Antengene Corporation, announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered Xpovio (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone (XBd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy and (2) in combination with dexamethasone (Xd) for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).

Xpovio is the first and only SINE approved by the TGA that helps to restore the body's own tumour suppressor pathways.

Condition: Multiple Myeloma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.